RF IDeas Adds to Badge Reader Portfolio with Introduction of Ultra-Compact pcProx® 13.56 MHz Nano
RF IDeas, Inc., the leading innovator and manufacturer of in-building identification and access control readers, today announced an addition to its pcProx® Nano line of readers, the pcProx® 13.56 MHz Nano contactless smart card reader. Available immediately, the 13.56 MHz Nano incorporates similar features to the pcProx desktop or surface-mount reader into an ultra-compact USB format. In addition to the popular pcProx 125 kHz Nano, the small size of the pcProx 13.56 MHz Nano makes it easy for embedding into monitor or keyboard housings and forklift control panels, connecting to multi-function printers, or for use with USB tablets - further simplifying the identification, authentication and access workflow.
This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20161215006215/en/
pcProx® 13.56 MHz Nano reader (Photo: Business Wire)
"The addition of this ultra-compact, multi-use 13.56 MHz Nano builds out our portfolio of card readers, meeting the needs of our partners and resellers who provide solutions for single sign-on, time and attendance, training compliance, point-of-sale, and secure management, among others,” said Tod Besse, vice president, sales and marketing, RF IDeas. "The feature-rich, small size makes this reader a value-added authentication tool for companies looking to comply with organizational identification guidelines without the bother of a bulky badge reader.”
The versatile 13.56 MHz Nano portfolio includes the following features:
- Four card configurations, allowing IT or security departments to leverage existing badges and seamlessly integrate additional badge types, especially important when companies merge
- Auto-tuning to counter the effects of card variability and environmental factors, ensuring optimal read performance
- Increased card type support including the addition of the NFC 1 (Topaz), iCLASS Seos, ISO 14443B, FeliCa (NFC 3), CEPAS, and Oyster
- Requires no additional drivers for simple plug-and-play operations
With the Software Developer’s Kit (SDK), independent developers can write applications that utilize badge identification information for a variety of operational applications.
To learn more about the 13.56 MHz Nano, click here.
About RF IDeas
RF IDeas, Inc. is a leader in the employee badge and card reader space for healthcare, manufacturing, government and enterprise. Partnering with leading technology companies, RF IDeas readers enable innovative solutions for single sign-on, secure printing, attendance tracking and other applications that require authentication. RF IDeas is a subsidiary of Roper Technologies. For more information about RF IDeas solutions, visit the Knowledge Center at https://www.rfideas.com/knowledge-center.
RF IDeas® and pcProx® are registered trademarks of RF IDeas, Inc. All other trademarks, service marks and product or service names are property of their respective owners.
RF IDeas, Inc.
Ph: (866) 439-4884 Ext: 480
Om Business Wire
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Følg saker fra Business Wire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Business Wire
Philip Morris International Releases Latest Scientific Update for Smoke-Free Products on Clinical Program12.12.2017 15:23 | Pressemelding
Philip Morris International Inc. (PMI) (NYSE/Euronext Paris: PM) today released its latest Scientific Update for Smoke-Free Products, a regular publication on its research efforts to develop and assess a range of smoke-free alternatives to cigarettes. The latest issue of the Scientific Update can be found at this link. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20171212005891/en/ Philip Morris International Releases Latest Scientific Update for Smoke-Free Products on Clinical Program (Photo: Business Wire) This issue of the Scientific Update provides a closer look at some of the principles and practices on which PMI’s scientific assessment program is built. Director Medical Affairs Dr. Patrick Picavet describes specific examples from PMI’s clinical program that highlight the company’s
Murex to Offer MX.3 Risk, Trading and Post-Trade Solutions on the AWS Cloud12.12.2017 14:00 | Pressemelding
Murex, an industry leader in trading, risk management and processing solutions for capital markets, announced they will run their MX.3 technology platform on Amazon Web Services, Inc. (AWS). With the acceleration of cloud adoption in capital markets, Murex and AWS agreed to collaborate to help clients migrate their Murex application workloads to the AWS Cloud. Murex clients are looking to consolidate more and more of their capital markets activity on the MX.3 platform and this means their need for infrastructure is increasing. New regulatory requirements are also driving financial organizations to use cloud to scale up their computing capacity. Murex is collaborating with AWS to meet the demand from clients to support deployment of the Murex offering on the AWS Cloud. Murex is working on the validation of a range of deployment scenarios, from using AWS Cloud for bursting grid
Darzalex®▼(daratumumab) Combination Regimen Significantly Improved Outcomes for Newly Diagnosed Multiple Myeloma Patients who are Transplant Ineligible12.12.2017 13:33 | Pressemelding
Janssen-Cilag International NV (“Janssen”) today announced data from the Phase 3 ALCYONE study, showing Darzalex® (daratumumab) in combination with bortezomib, melphalan and prednisone (VMP) significantly improved clinical outcomes, including reducing the risk of disease progression or death by 50 percent, in patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplantation (ASCT).1 These data were accepted as a late-breaking abstract (LBA) for presentation at the 59th American Society of Hematology (ASH) Annual Meeting in Atlanta, today at 7:30 a.m. ET (Abstract #LBA-4).1 Study findings were simultaneously published in the New England Journal of Medicine (NEJM) . 2 Daratumumab is currently indicated for use in combination with lenalidomide and dexamethasone, or bortezomib and dexamethasone, for
CTS Engines Announces Senior Management Hire12.12.2017 13:00 | Pressemelding
CTS Engines, the global leader for mature jet engine maintenance, announced today that it had hired Diane E. Cavuoto as Senior Vice President, Supply Chain, in an effort to continue to provide its customers with outstanding engine overhaul services. Ms. Cavuoto will be based in CTS’s Ft. Lauderdale headquarters and will report directly to Vesa Paukkeri, CTS’s President and Chief Operating Officer. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20171212005050/en/ Diane E. Cavuoto, Senior Vice President, Supply Chain, for CTS Engines (Photo: Business Wire) Ms. Cavuoto, most recently Vice President, Strategic Sourcing at Honeywell International, brings years of supply chain management experience to CTS. In her prior role at Honeywell, Ms. Cavuoto managed a global commodity team of 150 employees managing $4
MIPI Alliance Opens Access to its MIPI I3C Sensor Interface Specification12.12.2017 13:00 | Pressemelding
The MIPI® Alliance, an international organization that develops interface specifications for mobile and mobile-influenced industries, today announced it is opening access to its sensor interface specification, MIPI I3C. Starting today, all companies, including those not currently members of MIPI Alliance, may access the MIPI I3C v1.0 specification so they may evaluate the incorporation of the specification into their sensor integration plans and design applications. “MIPI I3C provides a welcome update to the I2C technology that has been widely adopted over the past 35 years. Extending access provides an opportunity to spur innovation and help other industries beyond mobile," said Joel Huloux, chairman of MIPI Alliance. "It helps MIPI members as well, because it supports greater adoption and interoperability, strengthens the ecosystem and provides for a richer
ADC Therapeutics Announces Interim Phase I Data from its Novel Antibody-Drug Conjugate ADCT-30112.12.2017 11:23 | Pressemelding
ADC Therapeutics (ADCT), an oncology drug discovery and development company that specializes in the development of proprietary Antibody Drug Conjugates (ADCs) targeting major cancers, today announced clinical data from two ongoing Phase I clinical trials evaluating ADCT-301 (camidanlumab tesirine or “Cami-T”) in important subtypes of lymphoma and leukemia. The data were presented at the 59th American Society of Hematology (ASH) Annual Meeting in Atlanta, USA. 1. Interim results of a Phase I open label, single agent, dose-escalating study of ADCT-301 evaluating tolerability, safety, pharmacokinetics and efficacy in patients with relapsed or refractory B-cell Hodgkin’s or non-Hodgkin’s lymphoma Dr. Steven M. Horwitz, Medical Oncologist at Memorial Sloan Kettering Cancer Center in New York City, and Principal Investigator, s
I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.Besøk vårt presserom